Namocell operates in the biotechnology sector, specializing in single cell isolation and sorting technologies. The company serves a diverse clientele including academic research institutions, pharmaceutical companies, and biotechnology firms. Namocell's core product is its benchtop cell sorter, which integrates Fluorescence-Activated Cell Sorting (FACS) with microfluidics to provide fast, gentle, and precise single cell isolation. The device supports multiple sorting modes, including Single Cell Dispensing, Rare Cell Enrichment, and Bulk Cell Sorting, making it versatile for various research applications. Namocell's business model revolves around the sale of these high-tech instruments and associated consumables, such as sterile disposable cartridges, which generate recurring revenue. The company also offers technical support and maintenance services, adding another revenue stream. Namocell's market is driven by the increasing demand for advanced cell engineering solutions, particularly in the fields of genomics, drug discovery, and personalized medicine. The company's innovative technology enhances research efficiency and accuracy, making it a valuable asset for its clients.

Keywords: single cell isolation, FACS, microfluidics, biotechnology, cell sorting, academic research, pharmaceutical, CRISPR, genomics, drug discovery.